SG11201809729XA - Palpable marker composition - Google Patents
Palpable marker compositionInfo
- Publication number
- SG11201809729XA SG11201809729XA SG11201809729XA SG11201809729XA SG11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA SG 11201809729X A SG11201809729X A SG 11201809729XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- composition
- administration
- kgs
- human
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 239000003550 marker Substances 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 abstract 3
- 150000001720 carbohydrates Chemical class 0.000 abstract 3
- 235000014633 carbohydrates Nutrition 0.000 abstract 3
- 239000007788 liquid Substances 0.000 abstract 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 abstract 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 abstract 1
- 238000006469 Jacobsen epoxidation reaction Methods 0.000 abstract 1
- PNIWLNAGKUGXDO-UHFFFAOYSA-N Lactosamine Natural products OC1C(N)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 PNIWLNAGKUGXDO-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 229960002442 glucosamine Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- DOVBXGDYENZJBJ-ONMPCKGSSA-N lactosamine Chemical compound O=C[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DOVBXGDYENZJBJ-ONMPCKGSSA-N 0.000 abstract 1
- 150000002597 lactoses Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 150000004044 tetrasaccharides Chemical class 0.000 abstract 1
- 150000004043 trisaccharides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0073—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form semi-solid, gel, hydrogel, ointment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650695 | 2016-05-20 | ||
| PCT/EP2017/062181 WO2017198858A1 (en) | 2016-05-20 | 2017-05-19 | Palpable marker composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809729XA true SG11201809729XA (en) | 2018-12-28 |
Family
ID=59070598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809729XA SG11201809729XA (en) | 2016-05-20 | 2017-05-19 | Palpable marker composition |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11058780B2 (ja) |
| EP (1) | EP3458029A1 (ja) |
| JP (1) | JP7086863B2 (ja) |
| KR (1) | KR102358040B1 (ja) |
| CN (1) | CN109475491B (ja) |
| AU (1) | AU2017266410B2 (ja) |
| BR (1) | BR112018073493A2 (ja) |
| CA (1) | CA3023928A1 (ja) |
| IL (1) | IL263071B (ja) |
| MX (1) | MX2018014087A (ja) |
| SG (1) | SG11201809729XA (ja) |
| WO (1) | WO2017198858A1 (ja) |
| ZA (1) | ZA201808532B (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110419160A (zh) | 2017-03-15 | 2019-11-05 | 株式会社村田制作所 | 电路模块、网络模块以及车载电子设备 |
| JP2021527704A (ja) * | 2018-06-19 | 2021-10-14 | デンマークス、テクニスケ、ウニベルシテットＤａｎｍａｒｋｓ Ｔｅｋｎｉｓｋｅ Ｕｎｉｖｅｒｓｉｔｅｔ | 基準マーカーとしての蛍光色素を含んでなる溶液 |
| WO2019243419A1 (en) * | 2018-06-19 | 2019-12-26 | Danmarks Tekniske Universitet | Brachygel for treatment of cancer and/or for guidance of surgery |
| WO2020249801A1 (en) * | 2019-06-12 | 2020-12-17 | Technical University Of Denmark | Dissacharide formulations for controlled drug release |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3733397A (en) | 1966-12-02 | 1973-05-15 | Pharmacia Ab | Method for the x-ray visualization of body cavities and a preparation for carrying out the method |
| SE344166B (ja) | 1966-12-13 | 1972-04-04 | Pharmacia Ab | |
| SE315974B (ja) | 1967-12-28 | 1969-10-13 | Pharmacia Ab | |
| US3804892A (en) | 1967-12-28 | 1974-04-16 | Pharmacia Ab | Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof |
| US3763227A (en) | 1967-12-28 | 1973-10-02 | Pharmacia Ab | Novel 3,5-substituted 2,4,6-triiodobenzoic acids and salts thereof |
| DE2628517C2 (de) | 1976-06-23 | 1985-02-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel |
| US4406878A (en) | 1978-08-02 | 1983-09-27 | Eastman Kodak Company | Iodinated contrast agent for radiography |
| IT1207226B (it) | 1979-08-09 | 1989-05-17 | Bracco Ind Chimica Spa | Derivati dell'acido 2,4,6-triiodo-isoftalico, metodo per la loro preparazione e mezzi di contrasto che li contengono. |
| DE3038853A1 (de) | 1980-10-10 | 1982-05-27 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii) |
| US4439356A (en) | 1981-03-03 | 1984-03-27 | Syva Company | Unsymmetrical fluorescein derivatives |
| EP0108638B1 (en) | 1982-11-08 | 1986-07-16 | NYEGAARD & CO. A/S | X-ray contrast agents |
| US5198136A (en) | 1986-12-23 | 1993-03-30 | Daikin Industries Ltd. | Iodine-containing compound, preparation thereof and block copolymer comprising the same |
| US5066580A (en) | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
| IT1245853B (it) | 1990-11-16 | 1994-10-25 | Bracco Spa | 1,3-bis(3-(mono o poliidrossi)acilamino-5-(mono o poliidrossi-alchil) aminocarbonil-2,4,6-triiodo-benzoil-amino)-idrossi- o idrossi-alchil- propani, loro metodo di preparazione e mezzi di contrasto roentgenografici che li contengono |
| US5750409A (en) | 1991-11-18 | 1998-05-12 | Boehringer Mannheim Gmbh | Pentacyclic compounds and their use as absorption or fluorescent dyes |
| DK0615438T3 (da) * | 1991-12-05 | 1996-11-11 | Mallinckrodt Veterinary Inc | En carbohydratglasmatrix til langvarig frigivelse af et terapeutisk middel |
| GB9303992D0 (en) | 1993-02-26 | 1993-04-14 | Nycomed Imaging As | Contrast agents |
| PT1006935E (pt) | 1995-06-07 | 2005-06-30 | Durect Corp | Sistema de entrega controlada liquido de alta viscosidade |
| US6413536B1 (en) | 1995-06-07 | 2002-07-02 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system and medical or surgical device |
| CA2229664A1 (en) | 1995-06-16 | 1997-01-03 | Biophysica, Inc. | Formyl derivatives as nonionic contrast media |
| US6008379A (en) | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
| US6270464B1 (en) * | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
| US6072069A (en) | 1998-11-04 | 2000-06-06 | Biophysica, Inc. | Biodegradable nonionic contrast media |
| BR9906240A (pt) | 1999-06-28 | 2002-07-23 | Temis Lostalo S A Lab | Composicoes injetáveis de carvão , em suspensão aquosa estável, método para prepará-las e método de marcacão pré-cirurgica na pesquisa de patologias mamárias nao palpáveis aplicando as referidas composições, uso do carvão ativado de granulometria seletiva para a preparacão das referidas composições |
| EP1186305A1 (en) | 2000-09-07 | 2002-03-13 | Schering Aktiengesellschaft | New brominated compounds as contrast media for X-ray mammography |
| EP1492776B1 (en) | 2002-03-27 | 2008-10-29 | FUJIFILM Corporation | Iodinated triglyceride analogs |
| US20050255045A1 (en) | 2004-05-13 | 2005-11-17 | Woltering Eugene A | Surgical marking composition and method |
| EP2231200A1 (en) | 2007-12-05 | 2010-09-29 | GE Healthcare AS | Contrast agents |
| US20090217932A1 (en) | 2008-03-03 | 2009-09-03 | Ethicon Endo-Surgery, Inc. | Intraluminal tissue markers |
| EP2782603A1 (en) | 2011-11-25 | 2014-10-01 | Danmarks Tekniske Universitet | Formulation of solid nano-sized particles in a gel-forming system |
| CA2913100C (en) * | 2013-05-24 | 2021-10-26 | Danmarks Tekniske Universitet | Gel formulations for guiding radiotherapy |
| WO2016079331A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for enhancing the effect of radiotherapy |
| EP3220887A1 (en) * | 2014-11-21 | 2017-09-27 | Technical University of Denmark | Gel formulations for local drug release |
| WO2016079332A1 (en) * | 2014-11-21 | 2016-05-26 | Technical University Of Denmark | Gel formulations for improving immunotherapy |
-
2017
- 2017-05-19 CA CA3023928A patent/CA3023928A1/en active Pending
- 2017-05-19 SG SG11201809729XA patent/SG11201809729XA/en unknown
- 2017-05-19 US US16/302,517 patent/US11058780B2/en active Active
- 2017-05-19 BR BR112018073493-4A patent/BR112018073493A2/pt not_active Application Discontinuation
- 2017-05-19 AU AU2017266410A patent/AU2017266410B2/en not_active Ceased
- 2017-05-19 JP JP2018561005A patent/JP7086863B2/ja active Active
- 2017-05-19 MX MX2018014087A patent/MX2018014087A/es unknown
- 2017-05-19 EP EP17730679.2A patent/EP3458029A1/en not_active Withdrawn
- 2017-05-19 CN CN201780023259.XA patent/CN109475491B/zh not_active Expired - Fee Related
- 2017-05-19 KR KR1020187035677A patent/KR102358040B1/ko active IP Right Grant
- 2017-05-19 WO PCT/EP2017/062181 patent/WO2017198858A1/en unknown
-
2018
- 2018-11-18 IL IL263071A patent/IL263071B/en unknown
- 2018-12-18 ZA ZA2018/08532A patent/ZA201808532B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019519522A (ja) | 2019-07-11 |
| CN109475491A (zh) | 2019-03-15 |
| MX2018014087A (es) | 2019-06-10 |
| US11058780B2 (en) | 2021-07-13 |
| CA3023928A1 (en) | 2017-11-23 |
| JP7086863B2 (ja) | 2022-06-20 |
| ZA201808532B (en) | 2020-02-26 |
| BR112018073493A2 (pt) | 2019-03-26 |
| AU2017266410B2 (en) | 2022-07-14 |
| KR102358040B1 (ko) | 2022-01-28 |
| EP3458029A1 (en) | 2019-03-27 |
| US20190275174A1 (en) | 2019-09-12 |
| CN109475491B (zh) | 2022-06-24 |
| WO2017198858A1 (en) | 2017-11-23 |
| AU2017266410A1 (en) | 2018-11-22 |
| IL263071B (en) | 2021-12-01 |
| KR20190026662A (ko) | 2019-03-13 |
| IL263071A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809729XA (en) | Palpable marker composition | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201900028VA (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201901444PA (en) | Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits, and methods | |
| SG11201809341PA (en) | Mobile robot | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201901374WA (en) | Antibiotic compounds | |
| SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201909837YA (en) | Methods for treating lung disorders | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer |